Profile picture

Doctor Rafael Rascon Sabido

Mexican Institute of Social Security (IMSS), Veracruz (Mexico)
Membership: ESC Professional Member
Follow
Biography
Dr. Rafael Rascón Sabido is a cardiologist and cardio-oncologist based in Boca del Río, Veracruz, Mexico, with specialties in Cardiology, Echocardiography, Heart Failire and Cardio-Oncology. He heads the Heart Failure Day Hospital and works in the Coronary Care Unit at UMAE No. 14 "Adolfo Ruiz Cortines" (IMSS), and maintains an active private practice at Millenium Medical Center. He also collaborates as an investigator with the clinical research site FAICIC leading RCTs.
Logo ESC

Contributor content

Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients
Presentation
Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients
The ACETAZ-HF trial: intravenous furosemide plus oral acetazolamide for rapid decongestion in acute HFrEF and sustained outpatient benefit
Presentation
The ACETAZ-HF trial: intravenous furosemide plus oral acetazolamide for rapid decongestion in acute HFrEF and sustained outpatient benefit
The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction
Presentation
The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction
The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
Presentation
The LIRA-HF trial: liraglutide in heart failure with reduced ejection fraction and obesity – a 30-month randomized trial
The FINO-HF trial: a randomised comparison of finerenone versus spironolactone in patients with heart failure with reduced ejection fraction - biomarker and clinical outcomes
Presentation
The FINO-HF trial: a randomised comparison of finerenone versus spironolactone in patients with heart failure with reduced ejection fraction - biomarker and clinical outcomes
The DIALY-MRA trial: a randomised comparison of finerenone versus spironolactone in patients on maintenance dialysis - a 3-month biomarker and safety study
Presentation
The DIALY-MRA trial: a randomised comparison of finerenone versus spironolactone in patients on maintenance dialysis - a 3-month biomarker and safety study